Danco Laboratories, the manufacturer of the abortion pill mifepristone, has filed an emergency appeal with the Supreme Court seeking to restore the ability of patients to obtain the drug through telehealth appointments and mail-order delivery. The appeal follows a federal appeals court ruling that blocked an FDA policy which had permitted that expanded access.
Mifepristone, approved by the FDA in 2000, is used in the majority of abortions in the United States and can legally be prescribed in states where abortion remains permitted. The contested FDA policy allowed physicians to prescribe the drug via telehealth and ship it directly to patients, a practice that became widespread during the COVID-19 pandemic and remained in place afterward.
The appeals court ruling found fault with the FDA's framework for allowing mail distribution of the drug, setting up a new Supreme Court review. Danco and abortion rights advocates argue that the ruling severely restricts access for patients in states where abortion is legal, particularly those in rural areas or without easy access to in-person medical facilities.
The Supreme Court has addressed mifepristone access before. In 2024, the Court unanimously dismissed a previous challenge on procedural grounds, leaving open the broader legal questions now being raised again through this appeal. The current filing asks the justices to intervene while the underlying litigation continues.
The case has drawn significant attention from healthcare providers, reproductive rights organizations, and anti-abortion advocates, each of whom have characterized the stakes differently. Abortion opponents argue the appeals court ruling restores appropriate oversight of a drug they contend carries serious health risks, while supporters of expanded access maintain that mifepristone has a well-documented safety record spanning decades.
Left-Leaning Emphasis
- NBC News frames the appeal as an urgent effort to protect patient access, particularly for those in rural or underserved areas who depend on telehealth.
- PBS NewsHour emphasizes the explainer angle, detailing what patients stand to lose if the Supreme Court declines to intervene.
- BBC highlights the broad impact on abortion access across the country, contextualizing the case within ongoing reproductive rights debates.
Right-Leaning Emphasis
- The Federalist frames the appeals court ruling as a victory, describing the FDA's mail policy as enabling the illegal distribution of a drug it characterizes as dangerous.
- The Federalist's headline uses the term 'traffick' to describe mail distribution, framing the issue primarily as one of legal and safety violations rather than access.